Liquidia (LQDA) – Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Liquidia (NASDAQ: LQDA) recently:

• 5/16/2026 – Liquidia was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/12/2026 – Liquidia had its price target raised by HC Wainwright from $55.00 to $67.00. They now have a “buy” rating on the stock.
• 5/12/2026 – Liquidia had its price target raised by Wells Fargo & Company from $51.00 to $62.00. They now have an “overweight” rating on the stock.
• 5/11/2026 – Liquidia had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $60.00 price target on the stock.
• 5/11/2026 – Liquidia had its price target raised by Needham & Company LLC from $54.00 to $70.00. They now have a “buy” rating on the stock.
• 5/11/2026 – Liquidia had its price target raised by BTIG Research from $50.00 to $59.00. They now have a “buy” rating on the stock.
• 5/5/2026 – Liquidia was upgraded by Zacks Research from “hold” to “strong-buy”.
• 4/21/2026 – Liquidia had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insiders Place Their Bets

In related news, Director Raman Singh sold 29,494 shares of the stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $60.13, for a total transaction of $1,773,474.22. Following the completion of the sale, the director owned 38,755 shares in the company, valued at approximately $2,330,338.15. This trade represents a 43.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Stephen M. Bloch sold 318,893 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $50.23, for a total value of $16,017,995.39. Following the sale, the director owned 1,870,042 shares of the company’s stock, valued at $93,932,209.66. This represents a 14.57% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 1,127,207 shares of company stock worth $50,967,227. Company insiders own 25.60% of the company’s stock.

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).